Trending archive
Every article that has appeared in Trending stays here. Search by title, journal, author or PMID, and narrow by date.
2000 articles
October 202624
Management of extravasations of enfortumab vedotin and pembrolizumab: a case report and mini review of the current literature.
A 56-year-old patient with metastatic urothelial carcinoma developed extravasation of enfortumab vedotin and pembrolizumab during the first treatment cycle after the port catheter dislocated from the cephalic vein.
Three traditional Chinese patent medicines combined with transarterial chemoembolization for primary liver cancer: A systematic review and Bayesian network meta-analysis.
This systematic review and Bayesian network meta-analysis assessed three traditional Chinese patent medicines combined with transarterial chemoembolization (TACE) for primary liver cancer.
Impact of Phosphatidylinositol 3-Kinase and B-Raf Mutations in Rat Sarcoma Wild-Type Metastatic Colorectal Cancer.
This systematic review and meta-analysis assessed whether PIK3CA and BRAF mutations were associated with outcomes among patients with RAS wild-type metastatic colorectal cancer receiving first-line EGFR inhibitor…
Multimodal imaging features of nuclear protein in testis carcinoma of the submandibular gland: a case report.
A 32-year-old man presented with a painless left submandibular mass that enlarged from 2 cm to approximately 4 cm within 1 month, with new ipsilateral pharyngeal and periauricular pain.
Tislelizumab-induced hyperamylasemia: Case report and safety analysis using the FAERS database.
A 69-year-old patient developed hyperamylasemia after six cycles of combination immunotherapy with pemetrexed, tislelizumab, and carboplatin. The authors attributed the elevated amylase to tislelizumab.
Case Report WIN-MTB-2024001 - WIN International Molecular Tumor Board: A 55-year-old male with glioblastoma exhibiting amplifications in MDM2 and EGFR.
A 55-year-old man with high-grade glioblastoma had next-generation sequencing findings that included MDM2 and EGFR amplifications and a CDKN2A frameshift mutation.
FDA Approval Summary: Erdafitinib for FGFR3-Altered Locally Advanced or Metastatic Urothelial Carcinoma.
This FDA approval summary describes evidence supporting erdafitinib for patients with FGFR3-altered locally advanced or metastatic urothelial carcinoma that progressed during or after at least one systemic therapy.
Intracranial metastasis as a mimic of amyloid-related imaging abnormalities.
A 79-year-old woman with biomarker-confirmed Alzheimer’s disease developed progressive vasogenic edema while receiving lecanemab.
Blood-based biomarkers in patients with recurrent, persistent, or metastatic endometrial cancer treated with olaparib and cediranib: Results from NRG-GY012.
This biomarker analysis of the phase 2 NRG-GY012 clinical trial assessed blood-based markers and outcomes among patients with recurrent, persistent, or metastatic endometrial cancer treated with olaparib, cediranib, or…
Primary Intermammary Breast Carcinoma Presenting With Direct Sternal Invasion: A Diagnostic Pitfall of Standard Screening Mammography.
An 85-year-old woman noticed a hard, non-tender sternal nodule despite an unremarkable screening mammogram 8 months earlier.
A Meta-Analysis on Outcomes of Zanidatamab Plus Chemotherapy in Patients with Advanced HER2-positive Gastroesophageal Adenocarcinoma.
This meta-analysis pooled outcomes from three clinical trials involving 685 patients with advanced HER2-positive gastroesophageal adenocarcinoma treated first-line with zanidatamab plus chemotherapy, with or without…
Phase I Trial of IL13Rα2-Targeted CAR T-cell Therapy for Recurrent Malignant Glioma: Clinical Results and Pharmacokinetics.
This single-centre, open-label phase I trial assessed intravenous autologous IL13Rα2-targeted CAR T cells in adults with recurrent, IL13Rα2-expressing grade 3–4 gliomas after standard treatment.
Circulating Thymidine Kinase Activity Predicts Survival and Optimal Treatment Sequencing in BRAF-Mutated Metastatic Melanoma in the SECOMBIT Trial.
This randomized phase II trial biomarker analysis evaluated circulating thymidine kinase activity (TKa) in patients with BRAF V600-mutated metastatic melanoma receiving targeted therapy (TT), immune checkpoint…
Brigimadlin versus Doxorubicin in Advanced Dedifferentiated Liposarcoma: Efficacy, Safety, and Translational Data from Brightline-1, a Randomized Phase II/III Trial.
Brightline-1 was a randomized phase II/III trial comparing first-line brigimadlin with doxorubicin in patients with MDM2-amplified, locally advanced or metastatic dedifferentiated liposarcoma.
Global Underutilization of Antiviral Therapy and Survival Outcomes in Hepatitis B Virus-Related Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis of 78 Studies and 68,243 Patients.
This systematic review and meta-analysis assessed antiviral use and its association with survival and hepatocellular carcinoma (HCC) recurrence in adults with HBV-related HCC.
Uniportal versus Multiportal Video-Assisted Thoracoscopic Surgery for Minimally Invasive Esophagectomy in Esophageal Cancer: A GRADE-Assessed Systematic Review and Meta-Analysis.
This GRADE-assessed systematic review and meta-analysis compared uniportal (uVATS) with multiportal video-assisted thoracoscopic surgery (mVATS) for minimally invasive esophagectomy in adults with esophageal cancer.
TRANSFORM-1 phase 3 study: efficacy and safety of navitoclax plus ruxolitinib in patients with untreated myelofibrosis.
TRANSFORM-1 was a multicentre, randomised phase 3 trial comparing navitoclax plus ruxolitinib with placebo plus ruxolitinib in Janus kinase inhibitor-naïve adults with intermediate-2 or high-risk myelofibrosis.
Association of immune checkpoint-related polymorphisms in PD-1, PD-L1, and CTLA-4 genes with susceptibility to genitourinary cancer: a meta-analysis.
This meta-analysis pooled evidence from 16 case-control studies examining six single-nucleotide polymorphisms in PD-1, PD-L1, and CTLA-4 genes and susceptibility to genitourinary cancers, including urothelial, renal…
Primary Hepatic Neuroendocrine Neoplasms: Systematic Review and Expert Pathologist Reappraisal Using the WHO 6th Edition Framework.
Primary hepatic neuroendocrine neoplasms (PHNENs) are exceedingly rare. Published evidence often lacks adequate clinicopathological support for a primary hepatic origin and uses inconsistent historical terminology.
AI-Based Pathology Classifier Predicts Sensitivity to Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer: A Biomarker Analysis of the ENZAMET Trial.
This prespecified biomarker analysis of the randomised ENZAMET trial assessed whether a locked artificial intelligence pathology image classifier (APIC) identified differential overall-survival benefit from enzalutamide…
Rilvegostomig for Metastatic Non-Small Cell Lung Cancer: A First-In-Human Phase I/II Clinical Study.
This first-in-human, multicenter, open-label phase I/II study evaluated rilvegostomig, a bispecific antibody targeting PD-1 and TIGIT, in patients with PD-L1-positive advanced or metastatic non-small cell lung cancer…
Efficacy and Safety of Necitumumab and Pembrolizumab Combination Therapy in Advanced Non-Small Cell Lung Cancer with ≥50% PD-L1 Expression: A Nonrandomized Phase II Trial.
This nonrandomized, multicenter, open-label, single-arm phase II trial evaluated first-line pembrolizumab plus necitumumab in 50 patients with previously untreated advanced NSCLC and PD-L1 tumor proportion score ≥50%.
Long-term Results of Multiantigen Stimulated Cell Therapy I, Alone or in Combination with Chemotherapy, as First-line Maintenance Therapy in Advanced Sarcoma: A Multicenter, Phase I Trial.
This multicenter, phase I trial evaluated multiantigen stimulated cell therapy I (MASCT-I), alone or with ifosfamide, as first-line maintenance therapy in 31 patients with advanced sarcoma whose disease was controlled…
Evidence on Glutathione and Boosters for Prevention of Chemotherapy-Induced Neuropathy: A Systematic Review and Network Meta-Analysis.
This systematic review and network meta-analysis compared glutathione (GSH) and GSH boosters for preventing chemotherapy-induced peripheral neuropathy (CIPN), drawing on 25 randomised controlled trials involving 1625…
Showing the most recent matches. Add a word or a date to reach older ones.
Stay updated for free
Get the 3 most interesting publications in one specialty each week.
Weekly email. Unsubscribe anytime.
Want this personalized?
Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.
- Your specialties
- Your filters and thresholds
- Clinical Research + Case Reports, tuned separately
- Automatic weekly delivery
- Audio and text
Prefer listening? Personalized audio digests are available with Pro.